Nvest Financial LLC Has $2.23 Million Holdings in Stryker Corporation $SYK

Nvest Financial LLC boosted its stake in Stryker Corporation (NYSE:SYK) by 33.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,776 shares of the medical technology company’s stock after purchasing an additional 1,689 shares during the quarter. Nvest Financial LLC’s holdings in Stryker were worth $2,226,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in SYK. Godfrey Financial Associates Inc. bought a new stake in shares of Stryker in the 4th quarter valued at about $26,000. Sankala Group LLC bought a new position in Stryker during the 4th quarter worth approximately $26,000. United Financial Planning Group LLC acquired a new position in Stryker during the third quarter valued at approximately $27,000. Atlas Capital Advisors Inc. bought a new stake in Stryker in the fourth quarter valued at approximately $27,000. Finally, DJE Kapital AG acquired a new stake in Stryker in the fourth quarter worth $28,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP M Kathryn Fink sold 5,220 shares of Stryker stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the sale, the vice president owned 13,137 shares in the company, valued at $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 323,264 shares of company stock valued at $100,659,489 in the last quarter. 4.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on SYK shares. Citigroup reduced their price target on shares of Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a research report on Tuesday, April 7th. Leerink Partners decreased their target price on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. Deutsche Bank Aktiengesellschaft set a $315.00 price target on Stryker in a report on Friday, May 1st. Robert W. Baird set a $385.00 price objective on Stryker in a report on Friday, May 1st. Finally, Barclays decreased their price objective on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research report on Monday, May 4th. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $395.33.

Stryker Price Performance

Shares of NYSE SYK opened at $326.41 on Monday. The company has a fifty day moving average price of $309.80 and a 200 day moving average price of $338.75. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $404.87. The firm has a market cap of $125.13 billion, a PE ratio of 37.78, a PEG ratio of 2.09 and a beta of 0.77. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Research analysts predict that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s payout ratio is presently 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.